openPR Logo
Press release

Ankylosing Spondylitis Market Treatment Advances and Global Growth Forecast

12-11-2025 01:41 PM CET | Health & Medicine

Press release from: Exactitude Consultancy

Ankylosing Spondylitis

Ankylosing Spondylitis

The Ankylosing Spondylitis (AS) Market focuses on therapies, diagnostics, and devices used for managing ankylosing spondylitis, a chronic inflammatory disease primarily affecting the spine and sacroiliac joints. AS is characterized by pain, stiffness, and progressive spinal fusion, which can significantly impact patient quality of life. Market offerings include biologic therapies, non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), physiotherapy tools, and diagnostic imaging solutions.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70982

Key Players
Major companies driving the market include:
• AbbVie - Humira (adalimumab) for biologic therapy
• Novartis - Cosentyx (secukinumab)
• Amgen - Enbrel (etanercept)
• Pfizer - Xeljanz (tofacitinib)
• Boehringer Ingelheim
• Eli Lilly and Company
• Mylan
• Sun Pharma
• Dr. Reddy's Laboratories
• Horizon Therapeutics
These players lead with biologics, biosimilars, and combination therapies targeting inflammatory pathways in AS patients.

Market Growth and CAGR
The global ankylosing spondylitis market is projected to grow steadily over the next decade, driven by rising prevalence, improved diagnosis rates, and adoption of advanced biologics. Estimates indicate a CAGR of approximately 7-8% during the forecast period (2024-2034). Market value is anticipated to exceed USD 5.2 billion by 2034, reflecting increased treatment uptake in both developed and emerging markets.

Key Market Drivers
• Rising Prevalence: The increasing incidence of ankylosing spondylitis globally, particularly in North America and Europe, is driving demand for effective therapies.
• Advancements in Biologic Therapies: IL-17 and TNF-alpha inhibitors are gaining preference due to their targeted mechanism and improved efficacy in symptom relief.
• Early Diagnosis and Awareness: Enhanced screening programs, improved imaging techniques (MRI and CT scans), and rising physician awareness contribute to early intervention and market growth.
• Favorable Reimbursement Policies: Government and private payer coverage for biologics and targeted therapies are encouraging broader patient access.

Explore Full Report here: https://exactitudeconsultancy.com/reports/70982/ankylosing-spondylitis-market

Trends and Opportunities
• Emerging Biosimilars: Cost-effective biosimilar versions of established biologics are expanding patient access in price-sensitive regions.
• Personalized Medicine: Integration of genetic testing and biomarkers enables tailored treatment strategies.
• Digital Health Integration: Remote monitoring and wearable devices for tracking disease activity are gaining adoption.
• Combination Therapy Research: New clinical trials combining biologics with DMARDs or NSAIDs aim to improve long-term outcomes.

Regional Insights
• North America dominates due to high healthcare spending, advanced biologic adoption, and awareness programs.
• Europe follows closely, with strong patient advocacy and favorable reimbursement systems.
• Asia-Pacific shows high growth potential due to increasing diagnosis rates, rising healthcare infrastructure, and growing awareness.

Conclusion
The Ankylosing Spondylitis Market is poised for robust growth driven by biologic therapy adoption, early diagnosis, and innovative treatment modalities. Opportunities in biosimilars, personalized medicine, and digital health solutions are expanding market potential, particularly in emerging economies. Stakeholders are focusing on R&D, strategic partnerships, and awareness campaigns to enhance treatment outcomes and patient quality of life.

This report is also available in the following languages : Japanese (強直性脊椎炎), Korean (강직성 척추염), Chinese (强直性脊柱炎), French (Spondylarthrite ankylosante), German (Spondylitis ankylosans), and Italian (Spondilite anchilosante), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/70982

Our More Reports:

Ankylosing spondylitis Patient Pool Market
https://exactitudeconsultancy.com/reports/71014/ankylosing-spondylitis-patient-pool-market

U.S. Ankylosing Spondylitis Treatment Market
https://exactitudeconsultancy.com/reports/50486/u-s-ankylosing-spondylitis-treatment-market

Ankylosing Spondylitis Medication Market
https://exactitudeconsultancy.com/reports/65992/ankylosing-spondylitis-medication-market

Golimumab (Simponi) Market
https://exactitudeconsultancy.com/reports/66417/golimumab-simponi-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ankylosing Spondylitis Market Treatment Advances and Global Growth Forecast here

News-ID: 4311849 • Views:

More Releases from Exactitude Consultancy

Moderate to Severe Acute Pain Market is projected to reach around USD 20.8 billion by 2034
Moderate to Severe Acute Pain Market is projected to reach around USD 20.8 billi …
Moderate to Severe Acute Pain Market Overview - The Moderate to Severe Acute Pain Market is witnessing substantial growth due to rising surgical procedures, growing prevalence of trauma and post-operative pain, and increasing awareness about effective pain management therapies. The market was valued at approximately USD 12.4 billion in 2024 and is projected to reach around USD 20.8 billion by 2034, registering a CAGR of 5.4%. Innovations in analgesics and multimodal
Heavy Metal Poisoning Market is projected to reach around USD 2.1 billion by 2034
Heavy Metal Poisoning Market is projected to reach around USD 2.1 billion by 203 …
Heavy Metal Poisoning Market Overview The Heavy Metal Poisoning Market is expanding steadily due to increasing exposure to toxic metals, growing industrialization, and rising awareness of health risks associated with heavy metals such as lead, mercury, arsenic, and cadmium. The market was valued at approximately USD 1.2 billion in 2024 and is projected to reach around USD 2.1 billion by 2034, growing at a CAGR of 5.8%. Enhanced diagnostic methods and
Chronic Venous Ulceration Market is projected to reach around USD 3.2 billion by 2034, expanding at a CAGR of 6.1%
Chronic Venous Ulceration Market is projected to reach around USD 3.2 billion by …
Chronic Venous Ulceration Market Overview The Chronic Venous Ulceration (CVU) Market is witnessing significant growth, driven by rising prevalence of venous insufficiency, aging populations, and growing awareness of advanced wound care solutions. Valued at approximately USD 1.8 billion in 2024, the market is projected to reach around USD 3.2 billion by 2034, expanding at a CAGR of 6.1%. Enhanced treatment modalities and increasing adoption of modern wound care technologies are
Acute Gout Flare Market Trends, Drivers, and Competitive Landscape
Acute Gout Flare Market Trends, Drivers, and Competitive Landscape
The Acute Gout Flare Market focuses on treatments that address sudden and severe episodes of gout-related joint pain, inflammation, and swelling. It includes NSAIDs, corticosteroids, colchicine formulations, biologics, and emerging targeted therapies that aim to rapidly reduce uric acid-induced inflammatory responses. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70980 Key Players • Novartis • Takeda • Horizon Therapeutics • Teijin Pharma • Grunenthal • Cipla • Sun Pharma • Mylan • Dr. Reddy's Laboratories • AbbVie Explore Full Report here: https://exactitudeconsultancy.com/reports/70980/acute-gout-flare-market Key Events in the Market • Development of targeted IL-1 inhibitors for acute

All 5 Releases


More Releases for Ankylosing

Ankylosing Spondylitis Market Trends That Will Shape the Next Decade: Insights f …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Ankylosing Spondylitis Market Size By 2025? The valuation of the ankylosing spondylitis sector has experienced robust expansion over the past few years, projected to advance from a figure of $5.9 billion in the year 2024 up to $6.34 billion by 2025, reflecting a compound annual
Ankylosing Spondylitis Market Surges With The Growing Geriatric Population World …
The Ankylosing Spondylitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Current Ankylosing Spondylitis Market Size and Its Estimated Growth Rate? The Ankylosing Spondylitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034.
Ankylosing Spondylitis Uncovered: Market Dynamics and Future Projections
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/2638 Introduction: The global ankylosing spondylitis market has been on a steady rise, reflecting the growing awareness and prevalence of this inflammatory condition. With a remarkable market size of $5,140.94 million in 2020, the projections indicate a substantial leap to $8,110.59 million by 2030. Ankylosing spondylitis, often misunderstood, is a complex disorder that affects the spine's flexibility and posture, potentially leading to severe complications if not managed effectively. Unveiling Ankylosing
Ankylosing Spondylitis Treatment Market to Witness Astonishing Growth by 2029
This Ankylosing Spondylitis Treatment Market research report focuses more on a number of distinctive as well as foremost market sectors. It further focuses market segmentation. Industry-specific interviews are carried out with market players to foresee future business growth. Various facets of the industry are also depicted here under each industry sector. Future development visions and a wide range of subjects are covered in this Ankylosing Spondylitis Treatment Market study report.
Ankylosing Spondylitis Market Overview With Detailed Analysis 2022-2028
According to Precision Business Insights (PBI), the latest report, ankylosing spondylitis market is expected to be valued at USD 5,460.5 million in 2022 which is expected to grow at a CAGR of 4.8% over 2022-2028. The primary factors that drive the market are the presence of biosimilars, usage of novel products, and increasing prevalence of ankylosing spondylitis. View the detailed report description here - https://precisionbusinessinsights.com/market-reports/ankylosing-spondylitis-market/ Retail Pharmacy to Dominate the
Ankylosing Spondylitis Market Challenges and Investment Opportunities by 2027
Allied Market Research published a report, titled, “Ankylosing Spondylitis Market: Global Opportunity Analysis and Industry Forecast 2020–2027.” According to the report, the global Ankylosing Spondylitis industry garnered $XX billion in 2019, and is expected to generate $xx billion by 2027, witnessing a CAGR of xx% from 2020 to 2027. Click Here To Access Sample Report https://www.alliedmarketresearch.com/request-sample/10631 Major players analyzed include AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen